High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: Prognostic indicators of progression-free and overall survival

被引:65
作者
Somlo, G
Doroshow, JH
Forman, SJ
OdomMaryon, T
Lee, J
Chow, W
Hamasaki, V
Leong, L
Morgan, R
Margolin, K
Raschko, J
Shibata, S
Tetef, M
Yen, Y
Simpson, J
Molina, A
机构
[1] CITY HOPE NATL MED CTR,DEPT BIOSTAT,DUARTE,CA 91010
[2] CITY HOPE NATL MED CTR,DEPT ANAT PATHOL,DUARTE,CA 91010
关键词
D O I
10.1200/JCO.1997.15.8.2882
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To examine the predictive value of tumor- and treatment-specific prognostic indicators of relapse-free survival (RFS) and overall survival (OS) in patients with high-risk breast cancer (HRBC) treated with high-dose chemotherapy (HDCT) and stem-cell rescue. Patients and Methods: Between June 1989 and September 1994, 114 patients with HRBC (stage II with greater than or equal to 10 axillary lymph nodes involved, stage IIIA, and stage IIIB inflammatory carcinoma) received adjuvant chemotherapy followed by HDCT with etoposide, cyclophosphamide, and either doxorubicin (CAVP) or cisplatin (CCVP). Variables analyzed included stage, tumor size, number of axillary nodes involved, grade and receptor status, and types of adjuvant chemotherapy and radiation therapy and HDCT. Results: With a median follow-up time of 46 months (range, 23 to 93), Kaplan-Meier estimates of 3.5-year OS for stage II, IIIA, and IIIB HRBC are 82% (95% confidence interval [CI], 67% to 97%), 79% (95% CI, 67% to 91%), and 72% (95% CI, 53% to 91%); RFS estimates are 71% (95% CI, 56% to 85%), 57% (95% CI, 43% to 72%), and 50% (95% CI, 29% to 71%) irrespective of the HDCT regimen. In univariate analysis, the risk of relapse was lower for patients with progesterone receptor (PR)-positive tumors (risk ratio [RR], 0.43; 95% CI, 0.22 to 0.81; P = .01) and higher for patients with inflammatory carcinoma (RR, 2.20; 95% CI, 1.02 to 4.76; P = .05). OS was better for patients with PR (RR, 0.16; 95% CI, 0.05 to 0.55; P = .003) and estrogen receptor (ER)-positive tumors (RR, 0.42; 95% CI, 0.17 to 1.02; P = .05); OS was worse for patients with high-grade primary tumors (RR, 4.08; 95% CI, 1.21-13.7; P = .02). In multivariate analysis, PR positivity was associated with improved RFS (P = .01) and OS (P = .001). Conclusion: HDCT in selected patients with HRBC is safe and warrants further evaluation. Patients with receptor-negative, high-grade, or inflammatory tumors require improvement in their therapeutic options. Better assessment of the role of HDCT awaits completion of ongoing randomized trials. (C) 1997 by American Society of Clinical Oncology.
引用
收藏
页码:2882 / 2893
页数:12
相关论文
共 51 条
[1]   16-WEEK DOSE-INTENSE CHEMOTHERAPY IN THE ADJUVANT TREATMENT OF BREAST-CANCER [J].
ABELOFF, MD ;
BEVERIDGE, RA ;
DONEHOWER, RC ;
FETTING, JH ;
DAVIDSON, NE ;
GORDON, GG ;
WATERFIELD, WC ;
DAMRON, DJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (07) :570-574
[2]   A PHASE-II STUDY OF HIGH-DOSE CYCLOPHOSPHAMIDE, THIOTEPA, AND CARBOPLATIN WITH AUTOLOGOUS MARROW SUPPORT IN WOMEN WITH MEASURABLE ADVANCED BREAST-CANCER RESPONDING TO STANDARD-DOSE THERAPY [J].
ANTMAN, K ;
AYASH, L ;
ELIAS, A ;
WHEELER, C ;
HUNT, M ;
EDER, JP ;
TEICHER, BA ;
CRITCHLOW, J ;
BIBBO, J ;
SCHNIPPER, LE ;
FREI, E .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (01) :102-110
[3]   RETRACTED: HIGH-DOSE CHEMOTHERAPY WITH HEMATOPOIETIC RESCUE AS PRIMARY-TREATMENT FOR METASTATIC BREAST-CANCER - A RANDOMIZED TRIAL (Retracted article. See vol. 19, pg. 2973, 2001) [J].
BEZWODA, WR ;
SEYMOUR, L ;
DANSEY, RD .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (10) :2483-2489
[4]  
Bitran JD, 1996, CLIN CANCER RES, V2, P1509
[5]  
BLUMENSCHEIN GR, 1988, P AM ASSOC CANC RES, V29, P196
[6]  
BONADONNA G, 1992, CANCER RES, V52, P2127
[7]  
BONADONNA G, 1995, JAMA-J AM MED ASSOC, V273, P542
[8]   CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL IN NODE-POSITIVE BREAST-CANCER - THE RESULTS OF 20 YEARS OF FOLLOW-UP [J].
BONADONNA, G ;
VALAGUSSA, P ;
MOLITERNI, A ;
ZAMBETTI, M ;
BRAMBILLA, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (14) :901-906
[9]   DOSE-RESPONSE EFFECT OF ADJUVANT CHEMOTHERAPY IN BREAST-CANCER [J].
BONADONNA, G ;
VALAGUSSA, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (01) :10-15
[10]  
BUZDAR AU, 1992, CANCER, V69, P448, DOI 10.1002/1097-0142(19920115)69:2<448::AID-CNCR2820690229>3.0.CO